Abstract-This study prospectively investigates the contribution of pregnancy complications and other reproductive age risk factors on the risk of subsequent cardiovascular disease death. Participants were 14 403 women in the Child Health and Development Studies pregnancy cohort drawn from the Kaiser Permanente Health Plan in California. Only women with nonmissing parity and no previously diagnosed heart conditions were included. A total of 481 had observed preeclampsia, and 266 died from cardiovascular disease. The median age at enrollment was 26 years, and the median follow-up time was 37 years. 3, 4 and that PE is one indicator of this health burden. 5 Following from the idea of pregnancy as a stress test, there is continuing debate around whether PE is only an indication of pre-existing risk factors or is itself an independent factor on the causal pathway to CVD. 4 -7 Complicating this debate, PE is a complex syndrome that has yet to be homogeneously diagnosed or defined. 8 Many researchers consider early or severe PE to be a different diagnosis than late PE that occurs near or at delivery and is usually milder. 9 -12 This is borne out by observations that early PE is linked with decreased gestational age and birth weight, as well as intrauterine growth restriction (IUGR) more generally, whereas late PE is characterized by a disproportionate number of high birth weight infants. 13, 14 The problem of overlapping risk factors (exemplified by the strong association between PE and IUGR) is ubiquitous in investigations of the association between PE and CVD. Traditional risk factors for CVD, such as increased body mass index and pre-existing hypertension, are also known to be associated with increased risk of PE. Such overlapping risk factors continue to provoke a multitude of questions about independence and confounding.
A growing body of literature indicates that preeclampsia (PE) in pregnancy may indicate increased risk for cardiovascular disease (CVD) later in life. 1, 2 It has been suggested that pregnancy forms an early stress test for preclinical later life risk factors 3, 4 and that PE is one indicator of this health burden. 5 Following from the idea of pregnancy as a stress test, there is continuing debate around whether PE is only an indication of pre-existing risk factors or is itself an independent factor on the causal pathway to CVD. 4 -7 Complicating this debate, PE is a complex syndrome that has yet to be homogeneously diagnosed or defined. 8 Many researchers consider early or severe PE to be a different diagnosis than late PE that occurs near or at delivery and is usually milder. 9 -12 This is borne out by observations that early PE is linked with decreased gestational age and birth weight, as well as intrauterine growth restriction (IUGR) more generally, whereas late PE is characterized by a disproportionate number of high birth weight infants. 13, 14 The problem of overlapping risk factors (exemplified by the strong association between PE and IUGR) is ubiquitous in investigations of the association between PE and CVD. Traditional risk factors for CVD, such as increased body mass index and pre-existing hypertension, are also known to be associated with increased risk of PE. Such overlapping risk factors continue to provoke a multitude of questions about independence and confounding.
This study investigates the predictors of PE to establish the sequence of maternal markers. Then the separate and combined effects of PE and other CVD risk factors are examined in an attempt to unravel their relationship with the causes of CVD death. This study further investigates the varying effects of PE on CVD death by gestational timing to clarify the spectrum of PE and its impact on subsequent CVD.
of California who became pregnant between 1959 and 1967. The CHDS cohort is socioeconomically broadly based with access to health care and representation from multiple race/ethnicity groups. A total of 20 530 pregnancies were observed in the CHDS. Women in the study received regular prenatal workups, including blood pressure and albumin readings, during each trimester. Blood pressures were taken by the nurses, using a standard protocol, at the regular prenatal clinic visits. 16 Information was collected on all of the pregnancies in the CHDS cohort including from interview at baseline (socioeconomic, demographic, behavioral variables, and pregnancy history and pregnancy-related variables) and from medical chart abstraction (prenatal measures [blood pressures and proteinuria], mother's medical conditions 6 months before and during pregnancy, and labor and delivery data. The institutional review board of the Public Health Institute approved the protocols for this study, and all of the human subjects gave full consent before the use of their information.
Cohort Surveillance
After active surveillance of the cohort ended in 1972, CHDS families were regularly matched to the California Department of Motor Vehicles (DMV) files and the California Vital Status records. The regular DMV matching provides a history of location and timing of residence, which allows identification of the population at risk for CVD death. All of the members of CHDS families are regularly matched to the DMV files on full name and birth date. For each match, all of the names that an individual has ever registered with the DMV, current and past, are used to determine a match. The DMV provides both residence and date at last active contact, so it is possible to establish if and when a subject is residing in a given area. Next, the complete CHDS cohort is matched to the California Vital Status records. A comparison of address history for all members of a family is made to verify that a match is accurate. Using all of the names that a subject has registered with the DMV to find matches within the California Vital Status records substantially reduces the likelihood that deaths are missed as a result of incomplete identifier information. The CHDS uses a rigorous protocol of both exact and probabilistic matching, followed by manual review, to determine acceptable matches. Death certificates are requested to further validate questionable matches. If an individual does not match to either the DMV or California Vital Status files, then the subject is considered lost to follow-up.
Study Sample
Initially, the analysis file was constructed at the pregnancy level to determine the comparability of risk in a primiparous sample versus a multiparous sample. For this comparison, we created one observation for each singleton pregnancy and then separate data sets for the primiparous and multiparous pregnancies. This resulted in 5749 primiparous pregnancies, of which 228 had observed PE and 57 had CVD death. Among the 10 253 multiparous pregnancies, 265 had observed PE and 223 had CVD death.
All of the associations were examined separately for primiparas and multiparas (Table S1 , available in the Online Data Supplement at http://hyper.ahajournals.org). Among primiparous pregnancies, 228 (4.0%) of 5749 women experienced PE, whereas only 265 (2.6%) of 10 253 multiparous pregnancies had an observed PE. This approximate doubling of the incidence of PE in primiparous pregnancies is common in the literature. 17 Because risks were comparable by parity for all of the factors examined, the groups were combined to allow sufficient power to examine the contribution of gestational timing of PE. Once it was determined that primiparous and multiparous pregnancies could be combined, the analysis file was constructed to have 1 observation for each woman to examine the outcome of CVD death. Parity was examined as a confounder of the other associations. We excluded multiple birth pregnancies and pregnancies missing on parity. We also excluded all of the pregnancies that ended in abortion or fetal death before 20 weeks' gestation and women with pre-existing heart conditions diagnosed before enrollment. This resulted in an analysis sample of 14 403 women, of whom 481 had observed PE (3.3%) and 266 died from CVD (64.99 per 100 000). The median follow-up time was 37 years, and median age at death from CVD was 65 years. The sample includes all race/ethnic groups: black (23%), Asian (4%), Hispanic/Latino (3%), white (68%), and other (2%). Women in the study sample had a mean age at first observed CHDS pregnancy of 26 years, and 69% were multiparous.
Measures
Results from the California Vital Status matches to CHDS files through year 2004 were used to append underlying cause and year of death. Because follow-up of the cohort spanned Ͼ40 years, codes for the underlying cause of death from several International Classification of Diseases (ICD) revisions were used to define CVD death, including the following: 420.1 for ICD-7; 410 and 412 for ICD-8; 410, 411, 414, and 429 for ICD-9, and I21 to I25 for ICD-10.
The primary analysis variables were PE, pre-existing hypertension, pre-existing diabetes mellitus, gestational hypertension, and having a baby with IUGR. These variables were coded as ever versus never for each CHDS subject. In this way, each woman has 1 observation with each of the above variables, coded as either 0 for no occurrence or 1 for Ն1 occurrence while under CHDS observation.
Proteinuria is defined as a reading of Ն1 (0.5% or 300 mg/24 hours) on a urine dipstick. Blood pressure is measured as systolic over diastolic pressure in millimeters of mercury. PE is defined as either of the following occurring after 20 weeks of gestation 18, 19 : Ն2 blood pressure readings Ͼ140/90 mm Hg and proteinuria or Ն2 systolic readings Ͼ140 mm Hg or Ն2 diastolic readings of Ͼ90 mm Hg and proteinuria.
Preexisting hypertension was defined as Ն1 blood pressure reading of Ն140/90 mm Hg before 20 weeks of pregnancy or doctor-diagnosed hypertension from the medical chart. Gestational hypertension was defined as Ն1 blood pressure reading of Ն140/ 90 mm Hg that developed after the 20th week of pregnancy and not accompanied by proteinuria. IUGR was defined as below the 10th percentile of z scores in birth weight by sex and gestational age for the CHDS distribution. Pre-existing diabetes mellitus was defined as doctor-diagnosed diabetes mellitus before the current pregnancy. Early onset PE was defined as onset of PE before 34 weeks of gestation. There were 22 subjects with an observed recurrence of PE between 1959 and 1967. Of these, 17 had onset only after 34 weeks' gestation, and 5 had Ն1 pregnancy with onset of PE by 34 weeks. These were not considered for separate examination because of small numbers, or they were self-reported prestudy recurrence because they could not be clinically defined.
Statistical Methods
Unadjusted CVD death rates were calculated per 100 000 personyears bracketed by 95% confidence limits. Hazard ratios were calculated using Cox proportional hazards models. The full model was constructed using all of the variables of interest that were either independently significant and/or confounders to the 10% level after mutual adjustment. Residence history and vital status were used to calculate the person-years of CVD death and to construct a censoring variable for the Cox proportional hazards models. Kaplan-Meier curves were constructed to further differentiate the effects of gestational timing of PE on CVD survival. All of the analyses were conducted using SAS 9.1. Table 1 shows that the unadjusted CVD death rates in the CHDS were higher for established CVD risk groups and other factors measured during pregnancy. Table 2 presents results for univariate and multivariate Cox models estimating risk of CVD death for the same exposures. Results from univariate models are very similar to those observed for data-based rates described above. These results do not change when the models are analyzed in a restricted data set (nϭ9491) with only nonmissing data for all of the variables of interest (data 
Results

Discussion
This article offers the unique contribution of following CVD risk factors from their association with PE (Table S2 ) through to their relationship with CVD death in a prospective cohort.
Many of the traditional CVD risk factors have been suggested as underlying factors for both diseases. 20 -22 However, because the higher risk of CVD death for women with PE is independent of body mass index, gestational hypertension, preexisting hypertension, preexisting diabetes mellitus, and having an IUGR child, it appears that PE may indicate more than simply a combination of other risk factors. Although there may be an underlying factor (eg, immune function, oxidative stress, and vascular factors) that explains the association between PE and CVD death, none has yet to be solidly identified.
One of the major weaknesses of this study is the inability to accurately assess PE and other events that occurred before or after the CHDS active study period. Although some misclassification of PE may have occurred, it would have led to an underestimation of the exposure and, therefore, biased the study toward null results. The strong positive association observed for PE and CVD death suggests that underestimation is low. Likewise, because of the small number of observed recurrent preeclamptic pregnancies, it was not feasible to investigate the association between PE recurrence and CVD. Another major weakness of this study is the inability to adjust for serum cholesterol level as a known predictor of CVD. 23 PE has long been strongly associated with hypertension and has also been shown to be connected to dyslipidemia. 24 Although it is rather unlikely that PE would be a strong or complete mediator of any cholesterol effects on CVD during the reproductive years, this study cannot investigate such a relationship. A weakness shared with other articles on this topic is the reliance on baseline behavior data as proxies for ongoing risk exposure. 1, 2 This is most problematic with the potential for change over time, as subjects age, in smoking status, in body mass index, indications of hypertension, and other known contributors to CVD. Despite many of the competing risk factors for CVD beginning by reproductive age, it is reasonable to assume that the increased risk of CVD death from these factors may be underestimated in studies that use baseline values, particularly for those *Variables beginning "Ever had" were recorded as ever occurring in a CHDS observed pregnancy or never occurring in a CHDS observed pregnancy.
†Univariate models are unadjusted and may be based on different sample sizes because of missing values (age: nϭ14 170; body mass index: nϭ10 828; current smoking: nϭ11 697; all others: nϭ14 320).
‡Full model contains variables that were either independently significant and/or confounders to the 10% level after mutual adjustment. The full model includes 9491 women. factors known to be strongly linked to aging. Regardless, these findings remain relevant to prevention, because they provide a much earlier target for intervention before other risk factors become clinically apparent. Finally, this study (even with 14 403 women) lacks the power to fully investigate the connections among all of the risk factors. In particular, the relationship between preeclamptic subgroups and traditional CVD risk factors cannot be elaborated because of the loss of power from the stratification of relatively small groups. In contrast, a major strength is that this study used detailed clinical records concurrent with pregnancy and before age of CVD risk to provide diagnostic criteria for defining PE, preexisting hypertension, and gestational hypertension. Additionally, the CHDS cohort provides Ͼ40 years of follow-up starting from early in a woman's pregnancy (before pregnancy complications like PE are diagnosed) and includes the ultimate outcome of CVD death. It is a major strength that this study investigates CVD mortality, a well-defined end point, instead of the disease's intermediary markers. Compared with the previous longitudinal studies of this topic, all but one of which are retrospective cohort studies, 1 this study allows for the investigation of PE as a mediator of major known CVD risk factors (with the exception of cholesterol) that temporally preceded the preeclamptic events, as well as robust assessment of confounding. Moreover, whereas Hannaford et al 25 provided the first evidence from a prospective cohort study, this is the first prospective cohort study on the topic that uses standardized definitions of PE and CVD. The long follow-up period allows observation through the age of peak risk for CVD and past what may be a latency between the initiation of endothelial dysfunction marked by PE and the emergence of CVD. 26 The exceptionally long follow-up period of this study additionally allows the findings of the previous literature, especially those of Irgens et al, 27 to be further generalized to women over the age of menopause. 28 Prospective data collection in a study population with access to health care reduces the chance that associations are the result of recall or detection bias.
It has been suggested that a history of PE might be used to target women at greater risk for CVD death for early intervention 1, 2, 4, 29, 30 and that these women may be more receptive to behavioral change. 31 This study supports the idea that there may be a benefit to early CVD screening for preeclamptic women even in the absence of other risk factors.
It is also of interest that gestational hypertension alone does not convey a higher risk of CVD death. As suggested by Bellamy et al, 1 the literature may be hindered by some level of misclassification between gestational hypertension and PE. For this reason, the separation of these 2 categories by strict clinical criteria in this study may provide an indication that de novo blood pressure elevation in pregnancy absent proteinuria may not be associated with CVD death.
Perspectives
This article allows further stratification of preeclamptic subgroups in an attempt to refine the level of potential risk by timing of onset during pregnancy. The findings are not surprising in light of the wealth of evidence that onset of PE earlier in gestation may have different causes and outcomes than PE developing later. These differences occur in markers of angiogenesis, [32] [33] [34] [35] dyslipidemia, 24 insulin resistance, 36, 37 and hemodynamics, 38 both before preeclamptic onset and postpartum. 39 Moreover, this study provides reinforcement to the currently sparse evidence that the differences in timing of preeclamptic onset play a role in long-term risk for CVD. 1, 27 Perhaps a more specific classification of PE by gestational onset can be used to further target women at the highest risk for CVD for intensive screening and early intervention.
